Cidara Therapeutics to Present New Data for Rezafungin and Influenza AVCs at the 21st ICHS Symposium

By Dr. Matthew Watson

SAN DIEGO, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced an oral presentation and four poster presentations at the 21st International Immunocompromised Host Society (ICHS) Symposium on Infections in the Immunocompromised Host, taking place virtually Feb. 17-19, 2021.

Read more:
Cidara Therapeutics to Present New Data for Rezafungin and Influenza AVCs at the 21st ICHS Symposium

Related Post


categoriaGlobal News Feed commentoComments Off on Cidara Therapeutics to Present New Data for Rezafungin and Influenza AVCs at the 21st ICHS Symposium | dataFebruary 11th, 2021

About...

This author published 3752 posts in this site.

Share

FacebookTwitterEmailWindows LiveTechnoratiDeliciousDiggStumbleponMyspaceLikedin

Comments are closed.





Personalized Gene Medicine | Mesenchymal Stem Cells | Stem Cell Treatment for Multiple Sclerosis | Stem Cell Treatments | Board Certified Stem Cell Doctors | Stem Cell Medicine | Personalized Stem Cells Therapy | Stem Cell Therapy TV | Individual Stem Cell Therapy | Stem Cell Therapy Updates | MD Supervised Stem Cell Therapy | IPS Stem Cell Org | IPS Stem Cell Net | Genetic Medicine | Gene Medicine | Longevity Medicine | Immortality Medicine | Nano Medicine | Gene Therapy MD | Individual Gene Therapy | Affordable Stem Cell Therapy | Affordable Stem Cells | Stem Cells Research | Stem Cell Breaking Research